Alluvi, previously BI 4744, presents a promising advance in weight control care. This dual stimulator targeting both GLP-1 and GIP receptors demonstrates compelling efficacy in research assessments, potentially https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/